Yang LIU,Pan ZHENG,Guo-Yun CHEN,Xi CHEN,Steve KUNKEL,Xincheng ZHENG
申请号：
US13426392
公开号：
US20120201819A1
申请日:
2012.03.21
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24 CD24 fragments, variants and derivatives, CD24Fc fusion proteins HMBG1-binding proteins, binding proteins to HMBG1 Box B antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B Siglec 10 agonists such as anti-Siglec 10 antibodies and combinations thereof to a patient.
